![](https://news.europawire.eu/wp-content/uploads/2023/03/OncoC4-licenses-next-generation-anti-CTLA-4-monoclonal-antibody-candidate-to-BioNTech-144x144.jpg)
(IN BRIEF) BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to develop an mRNA-based vaccine, BNT166, for the prevention of mpox (formerly monkeypox), an infectious disease that can have severe and life-threatening complications. … Read the full press release